Modality
ASO
MOA
CD47i
Target
FcRn
Pathway
Neuroinflam
Wilms
Development Pipeline
Preclinical
Apr 2021
→ Jun 2028
PreclinicalCurrent
NCT03536299
2,667 pts·Wilms
2021-04→2028-06·Recruiting
2,667 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-112.2y awayInterim· Wilms
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2028-06-11 · 2.2y away
Wilms
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03536299 | Preclinical | Wilms | Recruiting | 2667 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| BGN-3859 | BeiGene | Approved | PSMA |